120
edits
Changes
Plasma Cell Neoplasms Tables: Recurrent Cytogenomic Alterations (view source)
Revision as of 15:03, 13 July 2020
, 15:03, 13 July 2020adding gene links, partially complete
|1p32
|1p32
|Loss
|Loss
|''FAF1, CDKN2C''
|''[[FAF1]], [[CDKN2C]]''
|Poor prognostic marker
|Poor prognostic marker
|1, 2
|1, 2
|1p22.2-p22.1
|1p22.2-p22.1
|Loss
|Loss
|''BARHL2, TGFBR3, and others; HSP90B3P, TGFER3, BRDT, EPHAX4, BTBD8''
|''[[BARHL2]], [[TGFBR3]], and others; [[HSP90B3P]], [[TGFER3]], [[BRDT]], [[EPHAX4]], [[BTBD8]]''
|Prognostic
|Prognostic
|1, 3
|1, 3
|1p21.3
|1p21.3
|Loss
|Loss
|''SNX7''
|''[[SNX7]]''
|Recurrent
|Recurrent
|2
|2
|1p12
|1p12
|Loss
|Loss
|''MAN1A2, FAM46C, GDAP2''
|''[[MAN1A2]], [[FAM46C]], [[GDAP2]]''
|Recurrent
|Recurrent
|2
|2
|1q21.2-q23
|1q21.2-q23
|Gain
|Gain
|''CKS1B'' and ''ANP32E''
|''[[CKS1B]]'' and ''[[ANP32E]]''
|Recurrent
|Recurrent
|1
|1
|4p16.3
|4p16.3
|Loss
|Loss
|''FGFR3'' and ''WHSC1''
|''[[FGFR3]]'' and ''[[WHSC1]]''
|Recurrent
|Recurrent
|3
|3
|4p15.2
|4p15.2
|Loss
|Loss
|''LGI2, SEPSECS, PI4K2B'' and others
|''[[LGI2]], [[SEPSECS]], [[PI4K2B]]'' and others
|Recurrent
|Recurrent
|3
|3
|4q35.1
|4q35.1
|Loss
|Loss
|''DCTD, ING2,'' and others
|''[[DCTD]], [[ING2]],'' and others
|Recurrent
|Recurrent
|2
|2
|5q13.2
|5q13.2
|Loss
|Loss
|''OCLN, NAIP'', and others
|''[[OCLN]], [[NAIP]]'', and others
|Recurrent
|Recurrent
|2
|2
|6q11.1-q13
|6q11.1-q13
|Gain
|Gain
|''MTRNR2L9''
|''[[MTRNR2L9]]''
|Recurrent
|Recurrent
|3
|3
|6q16.3
|6q16.3
|Loss
|Loss
|''COQR, GRIK2''
|''[[COQR]], [[GRIK2]]''
|Recurrent
|Recurrent
|3
|3
|6q25.3
|6q25.3
|Loss
|Loss
|''IGFR3''
|''[[IGFR3]]''
|Recurrent
|Recurrent
|3
|3
|7p15.2
|7p15.2
|Gain
|Gain
|''CBX3, etc''
|''[[CBX3]], etc''
|Recurrent
|Recurrent
|3
|3
|8p23.1
|8p23.1
|Loss
|Loss
|''DEFB4'' and others
|''[[DEFB4]]'' and others
|Recurrent
|Recurrent
|2
|2
|8p21.3/p21.2
|8p21.3/p21.2
|Loss
|Loss
|''TNFRSF10B, DOCK5'' and others
|''[[TNFRSF10B]], [[DOCK5]]'' and others
|Recurrent
|Recurrent
|3
|3
|8q24.2
|8q24.2
|Gain/amplification and Loss
|Gain/amplification and Loss
|''MYC''
|''[[MYC]]''
|Recurrent
|Recurrent
|2
|2
Level 2: emerging evidence (by one large study or multiple case reports)
Level 2: emerging evidence (by one large study or multiple case reports)
Level 3: presumptive evidence (multiple case reports or expert opinion)<references />
Level 3: presumptive evidence (multiple case reports or expert opinion)
==Reference==
<references />